C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance

British Journal of Cancer

Volumn 83, Issue 12, 2000, Pages 1688-1695

  Deming, S L ^a   Nass, S J ^b   Dickson, R B ^a   Trock, B J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amplification; Breast cancer; C myc; Meta analysis; Prognostic markers

Indexed keywords

MYC PROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; ONCOGENE C MYC; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0034538306     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1522     Document Type: Article

References (54)

1. Proto-oncogene amplification and human breast tumor phenotype
2. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in colon carcinoma
3. C-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer
4. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumors: Correlation with steroid receptors
5. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer
6. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors
7. C-myc is an independent prognostic factor in postmenopausal breast cancer
8. Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erbB-2, and int-2 oncogene amplification and node invasiveness
9. Oncogene amplification per se: An independent prognostic factor in human breast cancer
10. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease
11. High cell kinetics is associated with amplification of the Int-2, Bcl-1, Myc and ErbB-2 protooncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers
12. Mapping of DNA amplification at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups
13. One gene amplification in promyelocytic leukaemaia cell line HL-60 and primary leukaemic cells of the same patient
14. C-myc target genes involved in cell growth, apoptosis, and metabolism
15. Meta-analysis: State-of-the-science
16. Alteration of morphogenesis by the c-myc oncogene in transplants of mammary gland
17. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas
18. Genetic alteration of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas
19. Planning the size and duration of a clinical trial studying the time to some critical event
20. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: Correlation with poor prognosis
21. Genetic studies of 457 breast cancers, clinicopathologic parameters compared with genetic alterations
22. Assessing the clinical impact of prognostic factors: When is 'statistically significant' clinically useful?
23. Assessing sequential oncogene amplification in human breast cancer
24. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
25. Amplification of c-myc, but not c-erbB2 is associated with high proliferative capacity in breast cancer
26. Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple noeoplasms and normal development
27. Amplification and expression of the c-myc oncogene in human lung cancer cell lines
28. Prognostic value of the erbB-2 and myc amplification in breast cancer imprints
29. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms
30. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas
31. Genomic alterations of the c-myc proto-oncogene in relation to the overexpression of c-erbB-2 and KI-67 in human breast and cervix carcinomas
32. Analysis of genetic alterations related to the development and progression of breast carcinoma
33. Defining a role for c-myc in breast tumorigenesis
34. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas
35. Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin D
36. Drug resistance, oncogenes, and anti-oncogenes in epithelial tumours
37. C-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse
38. Cathepsin-D and c-erb-B2 have an additive prognostic value for breast cancer patients
39. C-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients
40. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas
41. Apaf-1 and Caspase-9 in p53 dependent apoptosis and tumor inhibition
42. C-erbB-2/cerbA coamplification indicative of lymph node metastasis, and c-myc amplification of high tumor grade, in human breast carcinoma
43. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp 170 expression and its possible functional significance
44. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units hst-1/int-2 c-erbB-2/ear-1
45. Alteration to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
46. The molecular genetics of cellular oncogenes
47. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression
48. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis
49. Influence of c-myc on the progression of human breast cancer
50. Analysis of oncogenes and tumor suppressor genes in human breast cancer
51. Proto-oncogene abnormalities in human breast cancer: C-erbB-2 amplification does not correlate with recurrence of disease